Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]HRS-9190 in Healthy Participants
NCT07494175Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-9190, sponsored by Hengrui. Primary endpoints: Total radioactive recovery rate and cumulative total radioactive recovery rate of excreta, Percentage of unchanged HRS-9190 and its metabolites in the total radioactive exposure in plasma and 8 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
HRS-9190
Beyond the preview
Go deeper on NCT07494175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07494175.